Prevention of Serious Respiratory Syncytial Virus-Related Illness. II: Immunoprophylaxis
This article, published in Advances in Therapy, reviews the development and use of palivizumab, the only drug approved for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease. Palivizumab is a monoclonal antibody that can bind to a specific antigenic site on the virus and prevent cell-to-cell spread of infection. The authors outline the benefits and limitations of palivizumab and note ongoing research to develop new immunoprophylactic agents against RSV.
Author: Groothuis JR, Hoopes JM, Hemming VG
» Visit web page (English)
(Located at www.springerlink.com)
Citation: Groothuis JR, Hoopes JM, Hemming VG. Prevention of Serious Respiratory Syncytial Virus-Related Illness. II: Immunoprophylaxis. Advances in Therapy. 2011;28(2):110-125.
Resource types: Peer-reviewed journal
Diseases/vaccines: Respiratory syncytial virus (RSV)
Regions: North America and Europe